• Conditions and diseases

  • Blood and immune system •
  • Cancer •
  • Cardiovascular •
  • Central nervous system •
  • Digestive system •
  • Ear and nose •
  • Endocrine, nutritional and metabolic •
  • Eye •
  • Gynaecology, pregnancy and birth •
  • Infectious diseases •
  • Injuries, accidents and wounds •
  • Mental health and behavioural conditions •
  • Mouth and dental •
  • Musculoskeletal •
  • Respiratory •
  • Skin •
  • Urogenital

• Public health

  • Accidents and injuries •
  • Alcohol •
  • Behaviour change •
  • Cancer •
  • Cardiovascular disease •
  • Child health •
  • Child social care •
  • Chronic illness •
  • Diabetes •
  • Drugs •
  • Environmental health •
  • Infectious diseases •
  • Maternal health •
  • Mental health •
  • Non-communicable diseases •
  • Obesity and diet •
  • Occupational health •
  • Older people •
  • Physical activity •
  • Sexual health •
  • Smoking and tobacco •
  • Transport •
  • Vaccine preventable diseases •
  • Working with and involving communities

• Treatments, Procedures and Devices

  • Bones and joint surgery •
  • Cardiovascular surgery •
  • Cardiovascular system drug treatments •
  • Clinical devices •
  • Diagnostic imaging •
  • Diagnostic procedures •
  • Digestive tract and other abdominal organs surgery •
  • Drug treatments •
  • Endocrine system and breast surgery •
  • Eye surgery •
  • Nervous system surgery •
  • Radiotherapy •
  • Screening •
  • Surgical procedures •
  • Therapeutic procedures •
  • Tissue and organ donation •
  • Urogenital surgery

• Guidance by type

  • Clinical Guidelines •
  • Technology appraisals •
  • Public health guidance •
  • Diagnostics guidance •
  • Interventional procedures guidance •
  • Medical technologies guidance •
  • Cancer service guidance •
  • Quality standards

• Guidance by date

  • View the guidance by date published

About NICE guidance Close

Navigation

• NICE guidance

• Find guidance
• NICE Pathways
• Latest guidance
• Guidance by type
• Guidance in development
• How guidance is produced
• NICE guidance research recommendations
• Guidance for patients and public
• Other publications
• Patient safety solutions pilot
• Quality standards

Gastric cancer (HER2-positive metastatic) - trastuzumab

Trastuzumab for the treatment of HER2 positive advanced gastric cancer

Status:	History
Expected date of issue:	November 2010
Referral date:	March 2009
Wave:	19
Process:	STA
Notes: Cancer reform strategy Batch 5
Topic area: Cancer Digestive system

Project team | Schedule | Stakeholders | Project history | Key documents

 

NICE project team

Executive Lead:	Andrew Dillon
Technical Lead:	Joanne Holden
Communications manager:	Alice Law
Project manager:	Lori Farrar
Evidence review group:	NHS Centre for Reviews and Dissemination and Centre for Health Economics

Top

 

Provisional schedule

Closing date for invited submissions / evidence submission:	1 March 2010
1st appraisal committee meeting:	09 June 2010
2nd appraisal committee meeting	11 August 2010

Top

 

Consultees and commentators

Consultees   Commentators (no right of appeal)   Manufacturers/sponsors Roche Products (trastuzumab) Patient/carer groups None Professional groups Cancer Research UK Royal College of Nursing Royal College of Pathologists Royal College of Physicians United Kingdom Oncology Nursing Society Others Department of Health Welsh Assembly Government General British National Formulary Commissioning Support Appraisals Service Department of Health, Social Services and Public Safety for Northern Ireland NHS Quality Improvement Scotland Comparator manufacturers Bristol-Myers Squibb (cisplatin) Roche Products (capecitabine) Relevant research groups None Evidence Review Group National Institute for Health Research Health Technology Assessment Programme NHS Centre for Reviews & Dissemination and Centre for Health Economics -York Associated Guideline Groups National Collaborating Centre for Cancer Associated Public Health Groups None

Top

 

Project history

Date Update 19 November 2009 Following on from advice received from the manufacturer, this appraisal has been rescheduled to align with latest regulatory expectations. Therefore, we now anticipate that the appraisal will begin during late January 2010. The deadline for submissions is expected in approximately early April 2010. 13 August 2009 Please note that following on from advice received from the manufacturer, this appraisal has been rescheduled to align with latest regulatory expectations. Therefore, we now anticipate that the appraisal will begin during late January 2010. The deadline for submissions is expected in approximately early April 2010.

Top

 

Key documents

Gastric cancer (HER2-positive metastatic) - trastuzumab: equality impact assessment 24 November 2010 Gastric cancer (HER2-positive metastatic) - trastuzumab: final appraisal determination 29 September 2010 Gastric cancer (advanced HER-2 positive) - trastuzumab (herceptin): appraisal consultation 06 July 2010 NICE consults on new treatment for metastatic gastric cancer 06 July 2010 Gastric cancer (advanced HER-2 positive) - trastuzumab (herceptin): response to consultee and commentator comments on the provisional matrix 24 December 2009 Gastric cancer (advanced HER-2 positive) - trastuzumab (herceptin): response to consultee and commentator comments on the draft scope 24 December 2009 Gastric cancer (advanced HER-2 positive) - trastuzumab (herceptin): final scope 24 December 2009

This page was last updated: 24 November 2010